This article is more than 5 years old. Information may no longer be current.

RegeneRx files application for phase 2 trial of topical wound-healing drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BETHESDA, Md. — RegeneRx Biopharmaceuticals has filed an investigational new drug application with the U.S. Food and Drug Administration to conduct a phase 2 trial evaluating the efficacy of a drug intended to promote ocular wound healing, the company announced in a press release.

The company seeks to enroll diabetic patients undergoing vitrectomy who will have a small flap removed from their corneas. The trial will evaluate the efficacy of its Thymosin beta 4-based eye drop for treating corneal wounds.

In previous animal models, researchers found that Thymosin beta 4 reduced inflammation, prevented apoptosis, improved cellular adhesion and promoted re-epithelialization, the release said.